Specific Biologics
PrivateLast Round
Series A
Nov 2, 2026
Total Funding Raised
$36.84M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Specific Biologics operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series A round in November 2026.
Specific Biologics is a biotechnology company that develops precision gene-editing therapies for serious genetic diseases using its proprietary Dualase® platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Specific Biologics Comparables
Compare Specific Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shape Therapeutics | 79% | |
| Tune Therapeutics | 79% | |
| Tessera Therapeutics | 78% |
For institutional investors. Book with your work email.
Specific Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 2, 2026 | ||||
| Grant | Mar 18, 2026 | ||||
| Seed | Oct 10, 2023 | ||||
| Seed | Dec 16, 2021 | ||||
| Grant | Dec 7, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Specific Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hatteras Venture Partners | Series A |
| BDC Capital | Series A |
| DeepWork Capital | Series A |
| Genesys Capital | Series A |
| Cystic Fibrosis Foundation | Grant |
| Seido Capital | Series A |
| Lumira Ventures | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
$35M round led by Hatteras Venture Partners
- Aug 21, 2026
Monthly visitors increased 32% MoM, reaching 3.3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 3, 2026
Specific Biologics Inc. presents at the OBIO(R) Investment Summit and is an alumnus of the CAAP(R) program.
- receives_financingNov 2, 2026
Specific Biologics Inc. receives $35M Series A financing in Canada on Nov 2nd '26, led by Hatteras Venture Partners with participation from Lumira Ventures, adMare BioInnovations, Genesys Capital, BDC Life Sciences Venture Fund, DeepWork Capital, and Seido Capital to advance its lead gene-editing therapy for C9ORF72-associated ALS.
For institutional investors. Book with your work email.
Specific Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Specific Biologics's valuation, stock price, and market status.
Is Specific Biologics a public or private company?
Specific Biologics is a private company.
What is the current stock price of Specific Biologics?
Specific Biologics is a private company, so its shares have no public market price. Caplight tracks Specific Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Specific Biologics worth (valuation)?
Valuation information for Specific Biologics is not publicly available.
Can I buy Specific Biologics stock?
Specific Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Specific Biologics's last funding round?
Specific Biologics's most recent funding round was Series A on November 2, 2026.
Who are the main investors in Specific Biologics?
Key investors in Specific Biologics include Hatteras Venture Partners, Lumira Ventures.
Will Specific Biologics IPO soon?
No public IPO plans have been announced for Specific Biologics.
How can I track Specific Biologics secondary market activity?
Caplight tracks bids, offers, and trades in Specific Biologics's shares on secondary markets.